A study has shown that Roche's diabetic macular oedema (DME) therapy Vabysmo is effective in patients who identify as African ...
The two FDA-approved apps – RESET and RESET-O – have been re-launched by new owner PursueCare, which acquired them as part of ...
Vyloy is the first CLDN18.2-targeting drug to reach the US market but has already been approved in Japan as well as in the EU ...